Drug Type AAV based gene therapy |
Synonyms GF 1005, GF1005 |
Target |
Action modulators |
Mechanism SIRT6 modulators(NAD-dependent protein deacetylase sirtuin-6 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Sarcopenia | Preclinical | United Kingdom | 01 Nov 2023 |